

## SCIENTIFIC OPINION

### Scientific Opinion on the substantiation of a health claim related to iron and contribution to normal formation of haemoglobin and red blood cells pursuant to Article 14 of Regulation (EC) No 1924/2006<sup>1</sup>

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)<sup>2,3</sup>

European Food Safety Authority (EFSA), Parma, Italy

#### ABSTRACT

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and contribution to normal formation of haemoglobin and red blood cells. The food constituent, iron, which is the subject of the health claim, is sufficiently characterised. Contribution to normal formation of haemoglobin and red blood cells is a beneficial physiological effect for infants and young children. A claim on iron and contribution to normal formation of haemoglobin and red blood cells in the general population has already been assessed by the Panel with a favourable outcome. The Panel considers that the role of iron in normal formation of haemoglobin and red blood cells applies to all ages, including infants and young children (from birth to three years). The Panel concludes that a cause and effect relationship has been established between dietary intake of iron and contribution to normal formation of haemoglobin and red blood cells.

© European Food Safety Authority, 2014

#### KEY WORDS

iron, infants, children, haemoglobin, red blood cells, health claims

<sup>1</sup> On request from the Competent Authority of France following an application by Specialised Nutrition Europe (formerly IDACE), Question No EFSA-Q-2008-147, adopted on 11 December 2013.

<sup>2</sup> Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen. Correspondence: [nda@efsa.europa.eu](mailto:nda@efsa.europa.eu)

<sup>3</sup> Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the preparatory work on this scientific opinion.

Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the substantiation of a health claim related to iron and contribution to normal formation of haemoglobin and red blood cells pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA Journal 2014;12(1):3515, 10 pp. doi:10.2903/j.efsa.2014.3515

Available online: [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal)

## SUMMARY

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and contribution to normal formation of haemoglobin and red blood cells.

The scope of the application was proposed to fall under a health claim referring to children's development and health.

The food constituent that is the subject of the health claim is iron, which is an essential nutrient and is measurable in foods by established methods. The Panel considers that iron is sufficiently characterised.

The claimed effect proposed by the applicant is "role in the blood formation process". The target population proposed by the applicant is infants and young children from birth to three years of age. The Panel considers that contribution to normal formation of haemoglobin and red blood cells is a beneficial physiological effect for infants and young children.

A claim on iron and contribution to normal formation of haemoglobin and red blood cells in the general population has already been assessed by the Panel with a favourable outcome. The conclusion of the Panel was based on the well-established role of iron in preventing iron deficiency anaemia in humans.

The Panel considers that the role of iron in normal formation of haemoglobin and red blood cells applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between dietary intake of iron and contribution to normal formation of haemoglobin and red blood cells.

The following wording reflects the scientific evidence: "Iron contributes to normal formation of haemoglobin and red blood cells".

The Panel considers that in order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Tolerable Upper Intake Level has been set for iron in this age group.

## TABLE OF CONTENTS

Abstract .....	1
Summary .....	2
Table of contents .....	3
Background .....	4
Terms of reference .....	4
EFSA Disclaimer.....	4
Information provided by the applicant .....	5
Assessment .....	6
1. Characterisation of the food/constituent .....	6
2. Relevance of the claimed effect to human health.....	6
3. Scientific substantiation of the claimed effect .....	6
4. Panel’s comments on the proposed wording .....	7
5. Conditions and restrictions of use .....	7
Conclusions .....	8
Documentation provided to EFSA .....	8
References .....	8

## BACKGROUND

Regulation (EC) No 1924/2006<sup>4</sup> harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children's development and health in a Community list of permitted claims.

According to Article 15 of this Regulation, an application for authorisation shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).

## STEPS TAKEN BY EFSA

- The application was received on 14/02/2008.
- The scope of the application was proposed to fall under a health claim referring to children's development and health.
- On 26/03/2008, during the validation process of the application, EFSA sent a request to the applicant to provide missing information.
- On 22/08/2013, EFSA received the missing information as submitted by the applicant.
- The scientific evaluation procedure started on 04/10/2013.
- During its meeting on 11/12/2013, the NDA Panel, having evaluated the data submitted, adopted an opinion on the scientific substantiation of a health claim related to iron and contribution to normal formation of haemoglobin and red blood cells.

## TERMS OF REFERENCE

EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: iron and contribution to normal formation of haemoglobin and red blood cells.

## EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of iron, a positive assessment of its safety, nor a decision on whether iron is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.

---

<sup>4</sup> Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.

## **INFORMATION PROVIDED BY THE APPLICANT**

**Applicant's name and address:** Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des Nerviens, 1040 Brussels, Belgium.

### **Food/constituent as stated by the applicant**

According to the applicant, the food constituent for which the claim is made is iron.

### **Health relationship as claimed by the applicant**

According to the applicant, iron plays an important role in the blood formation process. Iron intake increases haemoglobin and serum ferritin concentrations depending on baseline haemoglobin levels.

### **Wording of the health claim as proposed by the applicant**

The applicant has proposed the following wording for the health claim: "Iron is important for blood formation".

As equivalent alternative wordings, the applicant has also proposed: "iron contributes to/is involved in/is important for/plays an important role for/is necessary for/participates to/is needed for/supports the development of/the normal development of/the normal function of/the function of blood formation/blood/red blood cells/blood haematopoiesis/red blood cell formation/haemoglobin-formation".

### **Specific conditions of use as proposed by the applicant**

According to the applicant, the target population is infants and young children from birth to three years of age. The claim should be used on foods that are exclusively intended for the category of infants and young children, and in line with the composition laid down in the specific directives (Directive 2006/141/EC; Directive 2006/125/EC; Directive 1999/21/EC).

According to the applicant, the quantity needed to achieve the claimed effect is:

- For follow-on formulae, the content in iron should be within the range set in Directive 2006/141/EC.
- For dietary foods for special medical purposes, the content in iron should be within the range set in Directive 1999/21/EC.
- For processed cereal-based foods and baby foods, the content in iron should be within the range set in Directive 2006/125/EC.
- For processed cereal-based foods and baby foods, the content in iron should reach at least 15 % of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15 % of 6 mg per 100 g or 100 ml or per serving, as reconstituted.
- For foods intended for infants and young children other than follow-on formulae, processed cereal-based foods and baby foods, the content in iron should reach at least 15 % of the Nutrient Reference Values set in Directive 2006/141/EC (replacing Directive 91/321/EC), i.e. 15 % of 8 mg per 100 ml product ready for use.

## ASSESSMENT

### 1. Characterisation of the food/constituent

The food constituent that is the subject of the health claim is iron, which is an essential nutrient and is measurable in foods by established methods.

Iron occurs naturally in foods in various forms, principally haem iron derived from haemoglobin and myoglobin in flesh foods, and non-haem iron in plant foods (IoM, 2001). Different forms of iron are authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006<sup>5</sup>, Annex I of Directive 2002/46/EC<sup>6</sup>, Annex III of Directive 2006/141/EC<sup>7</sup>, Annex IV of Directive 2006/125/EC<sup>8</sup>, Directive 2001/15/EC<sup>9</sup>). This evaluation applies to iron naturally present in foods and those forms authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006, Annex II of Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, Directive 2001/15/EC).

The Panel considers that the food constituent, iron, which is the subject of the health claim, is sufficiently characterised.

### 2. Relevance of the claimed effect to human health

The claimed effect proposed by the applicant is “role in the blood formation process”. The target population proposed by the applicant is infants and young children from birth to three years of age.

The Panel considers that contribution to normal formation of haemoglobin and red blood cells is a beneficial physiological effect for infants and young children.

### 3. Scientific substantiation of the claimed effect

The applicant performed a literature search in PubMed, Science Direct and Scopus using the following search terms: “blood formation”, “h\*ematopoiesis”, “\*h\*em\*”, “iron”, “ferritin”, “child\*”, “follow-on formula”, “complementary feeding”, “weaning food”, “bioavailability”, “iron toxicity”, “iron overload”. The applicant selected English and German publications from 2000 to 2009 of human intervention studies, reviews and meta-analyses in infants and children up to five years old.

The human intervention studies which were identified by the applicant as being pertinent to the health claim investigated the effect of iron supplementation or iron fortified formula/foods on plasma ferritin and haemoglobin in infants and young children (Singhal et al., 2000; Domellöf et al., 2001, 2002, 2008; Bramhagen et al., 2003; Friel et al., 2003; Lozoff et al., 2003; Nagpal et al., 2004; Wall et al., 2005; Ziegler et al., 2009). The applicant also identified two literature reviews as being pertinent to the health claim. The reviews describe randomised controlled trials investigating the effect of iron supplementation on prevention of iron deficiency and on haemoglobin concentrations in infants and young children (Iannotti et al., 2006; Gera et al., 2007). The applicant also provided *in vitro* and animal studies (Bouhallab et al., 2002; Etcheverry et al., 2004a, b; Kibangou et al., 2005; Rohner et

<sup>5</sup> Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.

<sup>6</sup> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.

<sup>7</sup> Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33.

<sup>8</sup> Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and young children. OJ L 339, 6.12.2006, p. 16–35.

<sup>9</sup> Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25.

al., 2007), three extracts from textbooks in German and six reports/papers from scientific bodies as being pertinent to the health claim (IoM, 2001; Aggett et al., 2002; INACG, 2002; JHCI, 2003; FAO/WHO, 2004; DGE, 2008).

Iron is an essential trace element that is mainly present in erythrocytes as haemoglobin, which transports oxygen to tissues (Hunt, 2005).

The Panel has already assessed a claim on iron and contribution to normal formation of haemoglobin and red blood cells with a favourable outcome (EFSA NDA Panel, 2009). The target population was the general population.

The conclusion of the Panel was based on the well-established role of iron in preventing iron deficiency anaemia in humans (IoM, 2001; FAO/WHO, 2004).

The Panel considers that the role of iron in normal formation of haemoglobin and red blood cells applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between dietary intake of iron and contribution to normal formation of haemoglobin and red blood cells.

#### **4. Panel's comments on the proposed wording**

The Panel considers that the following wording reflects the scientific evidence: "Iron contributes to normal formation of haemoglobin and red blood cells".

#### **5. Conditions and restrictions of use**

The Panel considers that in order to bear the claim:

- follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC;
- nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC<sup>10</sup>;
- processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC;
- other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/141/EC.

Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Tolerable Upper Intake Level has been set for iron (EFSA, 2004).

---

<sup>10</sup> Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, p. 29–36.

## CONCLUSIONS

On the basis of the data presented, the Panel concludes that:

- The food constituent, iron, which is the subject of the health claim, is sufficiently characterised.
- The claimed effect proposed by the applicant is “role in the blood formation process”. The target population proposed by the applicant is infants and young children from birth to three years of age. Contribution to normal formation of haemoglobin and red blood cells is a beneficial physiological effect for infants and young children.
- A cause and effect relationship has been established between dietary intake of iron and contribution to normal formation of haemoglobin and red blood cells.
- The following wording reflects the scientific evidence: “Iron contributes to normal formation of haemoglobin and red blood cells”.
- In order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Tolerable Upper Intake Level has been set for iron in this age group.

## DOCUMENTATION PROVIDED TO EFSA

Health claim application on iron and contribution to normal formation of haemoglobin and red blood cells pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0067\_FR). February 2008. Submitted by Specialised Nutrition Europe (formerly IDACE).

## REFERENCES

- Aggett PJ, Agostoni, C, Axelsson I, Bresson J-L, Goulet, O, Hernell, O, Koletzko B, Lafeber, HL, Michaelsen KF, Micheli J-L, Rigo J, Szajewska H and Weaver LT, 2002. ESPGHAN Medical Position Paper: Iron Metabolism and Requirements in Early Childhood. Do We Know Enough? A Commentary by the ESPGHAN Committee on Nutrition. *Journal of Pediatric Gastroenterology and Nutrition*, 34, 337-345.
- Bouhallab S, Cinga V, Ait-Oukhatar N, Bureau F, Neuville D, Arhan P, Maubois JL and Bougle D, 2002. Influence of various phosphopeptides of caseins on iron absorption. *Journal of Agricultural and Food Chemistry*, 50, 7127-7130.
- Bramhagen AC, Virtanen M, Siimes MA and Axelsson I, 2003. Transferrin receptor in children and its correlation with iron status and types of milk consumption. *Acta Paediatrica*, 92, 671-675.
- DGE (Deutsche Gesellschaft für Ernährung), 2008. Referenzwerte für die Nährstoffzufuhr. Korrigierter Nachdruck, Umschau/Braus, 174-178.

- Domellöf M, Cohen RJ, Dewey KG, Hernell O, Rivera LL and Lonnerdal B, 2001. Iron supplementation of breast-fed Honduran and Swedish infants from 4 to 9 months of age. *Journal of Pediatrics*, 138, 679-687.
- Domellöf M, Lind T, Lonnerdal B, Persson LA, Dewey KG and Hernell O, 2008. Effects of mode of oral iron administration on serum ferritin and haemoglobin in infants. *Acta Paediatrica*, 97, 1055-1060.
- Domellöf M, Lonnerdal B, Abrams SA and Hernell O, 2002. Iron absorption in breast-fed infants: effects of age, iron status, iron supplements, and complementary foods. *American Journal of Clinical Nutrition*, 76, 198-204.
- EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Tolerable Upper Intake Levels of Iron. *The EFSA Journal* 2004, 125, 1-34.
- EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific Opinion on the substantiation of health claims related to iron and formation of red blood cells and haemoglobin (ID 249, ID 1589), oxygen transport (ID 250, ID 254, ID 256), energy-yielding metabolism (ID 251, ID 1589), function of the immune system (ID 252, ID 259), cognitive function (ID 253) and cell division (ID 368) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal* 2009;7(9):1215, 20 pp. doi:10.2903/j.efsa.2009.1215
- Etcheverry P, Miller DD and Glahn RP, 2004a. A low-molecular-weight factor in human milk whey promotes iron uptake by Caco-2 cells. *Journal of Nutrition*, 134, 93-98.
- Etcheverry P, Wallingford JC, Miller DD and Glahn RP, 2004b. Calcium, zinc, and iron bioavailabilities from a commercial human milk fortifier: a comparison study. *Journal of Dairy Science*, 87, 3629-3637.
- FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization), 2004. Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation, Bangkok, Thailand.
- Friel JK, Aziz K, Andrews WL, Harding SV, Courage ML and Adams RJ, 2003. A double-masked, randomized control trial of iron supplementation in early infancy in healthy term breast-fed infants. *Journal of Pediatrics*, 143, 582-586.
- Gera T, Sachdev HP, Nestel P and Sachdev SS, 2007. Effect of iron supplementation on haemoglobin response in children: systematic review of randomised controlled trials. *Journal of Pediatric Gastroenterology and Nutrition*, 44, 468-486.
- Hunt JR, 2005. Iron. In: *Encyclopedia of Human Nutrition*. Eds Caballero B, Allen L, Prentice A. Elsevier, Oxford, UK.
- Iannotti LL, Tielsch JM, Black MM and Black RE, 2006. Iron supplementation in early childhood: health benefits and risks. *American Journal of Clinical Nutrition*, 84, 1261-1276.
- INACG (International Nutritional Anemia Consultative Group), 2002. Why iron is important and what to do about it: a new perspective. Office of Health, Infectious Disease and Nutrition, Bureau for Global Health, U.S. Agency for International Development, USA.
- IoM (Institute of Medicine), 2001. Dietary Reference Intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. National Academy Press, Washington DC, USA, 82-161.
- JHCI (Joint Health Claims Initiative), 2003. A list of well established nutrient function statements. A Report by the Joint Health Claims Initiative to the Food Standard Agency, London, UK.

- Kibangou IB, Bouhallab S, Henry G, Bureau F, Allouche S, Blais A, Guerin P, Arhan P and Bougle DL, 2005. Milk proteins and iron absorption: contrasting effects of different caseinophosphopeptides. *Pediatric Research*, 58, 731-734.
- Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T and Pino P, 2003. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics*, 112, 846-854.
- Nagpal J, Sachdev HP, Singh T and Mallika V, 2004. A randomized placebo-controlled trial of iron supplementation in breastfed young infants initiated on complementary feeding: effect on haematological status. *Journal of Health, Population and Nutrition*, 22, 203-211.
- Rohner F, Ernst FO, Arnold M, Hilbe M, Biebinger R, Ehrensperger F, Pratsinis SE, Langhans W, Hurrell RF and Zimmermann MB, 2007. Synthesis, characterization, and bioavailability in rats of ferric phosphate nanoparticles. *Journal of Nutrition*, 137, 614-619.
- Singhal A, Morley R, Abbott R, Fairweather-Tait S, Stephenson T and Lucas A, 2000. Clinical safety of iron-fortified formulas. *Pediatrics*, 105, E38.
- Wall CR, Grant CC, Taua N, Wilson C and Thompson JM, 2005. Milk versus medicine for the treatment of iron deficiency anaemia in hospitalised infants. *Archives of Disease in Childhood*, 90, 1033-1038.
- Ziegler EE, Nelson SE and Jeter JM, 2009. Iron supplementation of breastfed infants from an early age. *American Journal of Clinical Nutrition*, 89, 525-532.